Bayer data for kidney disease hope finerenone sets up filing...

Bayer’s blockbuster ambitions for diabetic kidney disease (DKD) drug candidate finerenone look a lot firmer with the publication of data from the phase 3 FIDELIO-DKD trial.

Study puts Jardiance in hot pursuit of AZ’s Farxiga in heart...

The FDA’s approval of AstraZeneca’s SGLT2 inhibitor Farxiga in heart failure was a first for the class, but Boehringer Ingelheim and Eli Lilly are closing the gap with a positi

Janssen taps wearable tech in Invokana heart failure trial

Boehringer, Lilly start acute heart failure trial with Jardi...

AZ’s Forxiga gets heart claim data on its EU label

FDA fast-tracks Lilly/Boehringer’s Jardiance for heart failu...